Imugene share price lifts 11% on clinical trial update

Imugene shares are flying higher today.

| More on:
A man in a wheelchair stretches both arms into the air in success.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • Imugene shares lift 11% to 30 cents in late morning trade
  • The company announced that the first patient from the third cohort in the Checkvacc study has been dosed
  • The aim of the trial is to activate the immune system of cancer patients to treat and eradicate tumours

The Imugene Limited (ASX: IMU) share price is soaring on Wednesday.

This comes after the company provided an update on its clinical trial of its oncolytic virotherapy candidate, Checkvacc.

The novel treatment aims to activate the immune system of cancer patients to treat and eradicate tumours.

In late morning trade, shares in the immuno-oncology company are up 11.11% to 30 cents.

What did Imugene announce to the ASX?

In its release, Imugene advised that City of Hope has dosed the first patient from the third group of participants in the Checkvacc phase 1 clinical trial.

City of Hope is one of the largest cancer research and treatment organisations in the United States.

The Checkvacc study is recruiting patients who suffer from triple negative breast cancer (TNBC).

Further, the primary goal of the study is to determine safety limits and decide on the optimal dosage of Checkvacc against metastatic TNBC.

Imugene noted that the current trial design involves a dose escalation. Thereafter, an expanded group of 12 patients will receive the final dose.

Commenting on the update, Imugene managing director and CEO Leslie Chong said:

We are pleased with the continued progress being made in this trial as we dose the first patient in cohort 3.

From cohorts 1 & 2 we've continued to see early positive results in oncolytic virus infection and replication in the TNBC tumours and importantly there remains no observed toxicity.

Checkvacc has the potential to improve clinical response and survival in this indication where there are currently no meaningful treatments, and we are eager to deliver on that.

Imugene share price snapshot

Despite climbing 30% in the past month, the Imugene share price has fallen 25% in 2022.

The company's shares hit a 52-week low of 13 cents on 14 June, before gradually moving higher.

Imugene presides a market capitalisation of approximately $1.58 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »